AC Immune SA - Company Profile

Powered by

All the data and insights you need on AC Immune SA in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date AC Immune SA Strategy Report

  • Understand AC Immune SA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

AC Immune SA: Overview

Select Item

AC Immune SA (AC Immune) is a clinical-stage biopharmaceutical company that discovers, designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company to design, discover and develop antibodies, small molecules and vaccines. AC Immune’s product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company’s lead product candidate crenezumab, is a monoclonal antibody that targets abeta in cognitive healthy individuals who are at risk of developing familial Alzheimer’s Disease (fAD). AC Immune is headquartered in Lausanne, Switzerland.

 Gain a 360-degree view of AC Immune SA and make more informed decisions for your business Gain a 360-degree view of AC Immune SA and make more informed decisions for your business Find out more
Headquarters Switzerland
Address Epfl Innovation Park, Building B, Lausanne, 1015
Website www.acimmune.com
Telephone 41 21 3459121
No of Employees 126
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ACIU (NASD)
Revenue (2022) $4.1M
EPS XYZ
Net Income (2022) XYZ 3.1% (2022 vs 2021)
Market Cap* $268.4M
Net Profit Margin (2022) XYZ -4,470.5% (2022 vs 2021)
* As of and is in US$
View AC Immune SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

AC Immune SA premium industry data and analytics

40+

Catalyst Calendar

Proactively evaluate AC Immune SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for AC Immune SA’s relevant decision makers and contact details.

20+

Pipeline Drugs

Identify which of AC Immune SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Clinical Trials

Determine AC Immune SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

10+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Pipeline
Crenezumab (anti-Abeta antibody)- Alzheimer’s Disease
ACI-24 (anti-Abeta vaccine)- Alzheimer’s Disease
XYZ
XYZ
XYZ
Understand AC Immune SA portfolio and identify potential areas for collaboration Understand AC Immune SA portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In June, the company received FDA fast track designation for anti-amyloid-beta active immunotherapy, ACI-24.060, to treat Alzheimer’s disease.
2022 Corporate Changes/Expansions In October, the company opened new centers in phase 1b/2 trial evaluating ACI-24 targeting Abeta In Alzheimer’s disease and down yyndrome.
2021 Acquisitions/Mergers/Takeovers In July, the company announced the acquisition of AFFiRiS’ anti-alpha-synuclein programs.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters AC Immune SA Tillotts Pharma AG Idorsia Pharmaceutical Ltd Addex Therapeutics Ltd Pharnext SA
Headquarters Switzerland Switzerland Switzerland Switzerland France
City Lausanne Rheinfelden Allschwil Plan-Les-Ouates Issy-Les-Moulineaux
State/Province - Aargau - - Ile-de-France
No. of Employees 126 373 636 22 44
Entity Type Public Private Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Douglas E. Williams, Ph.D. Chairman Executive Board - 64
Andrea Pfeifer, Ph.D. Chief Executive Officer; Director Executive Board 2016 65
Jean-Fabien Monin Chief Administrative Officer Senior Management 2015 52
Johannes R. Streffer Chief Medical Officer Senior Management 2021 54
Marie Kosco- Vilbois, Ph.D. Chief Scientific Officer Senior Management - 65
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into AC Immune SA key executives to enhance your sales strategy Gain insight into AC Immune SA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward